Logotype for USANA Health Sciences Inc

USANA Health Sciences (USNA) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for USANA Health Sciences Inc

Q3 2024 earnings summary

19 Jan, 2026

Executive summary

  • Q3 2024 net sales declined 6.2% year-over-year to $200.2 million, with diluted EPS at $0.56, down from $0.59 in Q3 2023, and active customers decreased to 452,000.

  • Net earnings for Q3 2024 were $10.6 million, down from $11.3 million in Q3 2023, reflecting lower sales and higher operating expenses.

  • Management cited continued headwinds in key markets, especially China, but highlighted progress on strategic initiatives, product innovation, and global expansion, including India.

  • The company operates in 25 markets, with about 90% of net sales generated outside the US, and maintains a low capital intensity business model with strong cash flow and no debt.

  • Increased promotional activity is planned for Q4 to support business momentum, with updated fiscal 2024 guidance reflecting these efforts.

Financial highlights

  • Q3 2024 net sales were $200.2 million, down 6.2% year-over-year; net earnings were $10.6 million, and diluted EPS was $0.56.

  • Gross margin for Q3 2024 was 80.4%, up from 80.1% in Q3 2023, driven by lower material costs and favorable market mix.

  • Cash and cash equivalents as of Q3 2024 were $365 million, with no debt.

  • Free cash flow for the trailing twelve months was $74 million, with a free cash flow margin of 9%.

  • Operating cash flow for the first nine months of 2024 was $55.2 million, up from $44.6 million in the prior-year period.

Outlook and guidance

  • Fiscal 2024 net sales guidance is $850 million, with diluted EPS of $2.45 and operating margin of 8.5%.

  • Fourth quarter guidance includes higher promotional spending, expected to impact margins and EPS.

  • Management does not expect recent stimulus in China to impact near-term results.

  • Product pipeline for 2025 is robust, with significant upgrades and new launches planned, especially in the nutritionals category.

  • Remediation of material weaknesses in IT general controls is ongoing, with completion expected before year-end 2024.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more